Ardelyx 5/1/2025 Earnings Report

Ardelyx EPS Results

• Actual EPS: -$0.17
• Consensus EPS: -$0.10
• Beat/Miss: Missed by -$0.07
• One Year Ago EPS: -$0.11

Ardelyx Revenue Results

• Actual Revenue: $74.11 million
• Expected Revenue: $79.40 million
• Beat/Miss: Missed by -$5.29 million
• YoY Revenue Growth: +61.10%

Ardelyx Announcement Details

• Date: 5/1/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Ardelyx (NASDAQ:ARDX), a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.